Publicaciones científicas

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

11-may-2020 | Revista: Nature Medicine

Schalper KA (1), Carleton M (2), Zhou M (3), Chen T (3), Feng Y (3), Huang SP (3), Walsh AM (4), Baxi V (4), Pandya D (5), Baradet T (2), Locke D (2), Wu Q (5), Reilly TP (5), Phillips P (2), Nagineni V (6), Gianino N (6), Gu J (7), Zhao H (7), Perez-Gracia JL (8,9), Sanmamed MF (8,9,10,11), Melero I (12,13,14).

(1) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. kurt.schalper@yale.edu.
(2) Department of Translational Medicine, Bristol-Myers Squibb, Princeton, NJ, USA.
(3) Department of Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA.
(4) Department of Translational Bioinformatics, Bristol-Myers Squibb, Princeton, NJ, USA.
(5) Department of Research and Early Development, Bristol-Myers Squibb, Princeton, NJ, USA.
(6) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
(7) Department of Biostatistics, School of Public Health, Yale University, New Haven, CT, USA.
(8) Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
(9) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(10) Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
(11) Department of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
(12) Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
(13) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(14) Department of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.


Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers.

Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.

CITA DEL ARTÍCULO  Nat Med. 2020 May;26(5):688-692. doi: 10.1038/s41591-020-0856-x. Epub 2020 May 11